- Home
- GROW vs SKYE Comparison
GROW vs SKYE Comparison
Compare GROW & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROW | SKYE |
|---|---|---|
| Founded | 1968 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 27.1M |
| IPO Year | 1995 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GROW | SKYE |
|---|---|---|
| Price | $2.91 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 28.6K | ★ 179.7K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $23,850,609.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.23 | $0.57 |
| 52 Week High | $3.65 | $5.75 |
Technical Indicators
Market Signals| Indicator | GROW | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 71.32 | 44.02 |
| Support Level | $2.39 | $0.70 |
| Resistance Level | $3.43 | $0.83 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 87.00 | 27.04 |
Price Performance
Historical ComparisonAbout GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.